Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director | September 03, 2026 | September 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 03, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 328,436 |
Ending reported balance
After 2026-09-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-03 · Sale · Disposed 7,012 · Balance 341,424 F1: This transaction was executed in multiple trades at prices ranging from $60.435 to $61.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-09-03 · Sale · Disposed 6,814 · Balance 334,610 F2: This transaction was executed in multiple trades at prices ranging from $61.435 to $62.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 3 · 2026-09-03 · Sale · Disposed 6,174 · Balance 328,436 F3: This transaction was executed in multiple trades at prices ranging from $62.50 to $62.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $60.435 to $61.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F2: This transaction was executed in multiple trades at prices ranging from $61.435 to $62.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $62.50 to $62.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 8, 2026 23:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,174 | $62.61 | $386,533.15 |
DisclosureSEC source: 0001610717-26-000405 · form4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,436 F3 · price: This transaction was executed in multiple trades at prices ranging from $62.50 to $62.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 23:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,814 | $62.11 | $423,205.27 |
DisclosureSEC source: 0001610717-26-000405 · form4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,610 F2 · price: This transaction was executed in multiple trades at prices ranging from $61.435 to $62.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 23:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,012 | $60.66 | $425,333.19 |
DisclosureSEC source: 0001610717-26-000405 · form4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,424 F1 · price: This transaction was executed in multiple trades at prices ranging from $60.435 to $61.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 16:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,000 | $58.73 | $176,175.00 |
DisclosureSEC source: 0001610717-26-000358 · form4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,436 Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 16:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 17,000 | $57.58 | $978,880.40 |
DisclosureSEC source: 0001610717-26-000358 · form4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,436 F1 · price: This transaction was executed in multiple trades at prices ranging from $57.50 to $58.1525. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 19:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 8,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000194 · form4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,436 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 17:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 15,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000170 · form4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,607 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2025, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 16:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 8,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000330 · form4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,250 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2024, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 17:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 4,661 | $0.00 Strike: $57.62 | $0.00 |
DisclosureSEC source: 0001610717-23-000175 · form4.xml · derivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,661 Underlying: Class A Common Stock · 4,661 shares Expires 2033-06-14 F2 · derivative.exercise_date: 1/12th of the total number of shares subject to the option vest on each monthly anniversary measured from June 14, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 17:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 1,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000175 · form4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,601 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 18:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 10,000 | $54.89 | $548,894.00 |
DisclosureSEC source: 0001610717-23-000099 · form4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,736 F1 · price: This transaction was executed in multiple trades at prices ranging from $54.47 to $55.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 17:18 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $39.62 | $0.00 |
DisclosureSEC source: 0001567619-22-013121 · doc1.xml · derivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Class A Common Stock · 5,300 shares Expires 2032-06-15 F2 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one-twelfth of the shares on July 15, 2022 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 17:18 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013121 · doc1.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,736 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-fourth of the RSUs, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, shall vest on August 21, 2022 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 30, 2021 Filed Jan 4, 2022 18:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,782 | $151.57 | $270,088.83 |
DisclosureSEC source: 0001567619-22-000366 · doc1.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,616 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $151.02 to $151.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 30, 2021 Filed Jan 4, 2022 18:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,218 | $150.56 | $484,500.79 |
DisclosureSEC source: 0001567619-22-000366 · doc1.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,398 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $150.00 to $150.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 17:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $155.55 | $15,555.00 |
DisclosureSEC source: 0001567619-21-021614 · doc1.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,616 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 17:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $154.02 | $15,402.00 |
DisclosureSEC source: 0001567619-21-021614 · doc1.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,716 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 17:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $151.79 | $166,972.52 |
DisclosureSEC source: 0001567619-21-021614 · doc1.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,816 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $151.53 to $152.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 17:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,700 | $151.10 | $256,868.81 |
DisclosureSEC source: 0001567619-21-021614 · doc1.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,916 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $151.00 to $151.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 17:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,000 | $150.51 | $301,021.60 |
DisclosureSEC source: 0001567619-21-021614 · doc1.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,616 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $150.00 to $150.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 19:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $160.32 | $16,032.00 |
DisclosureSEC source: 0001567619-21-020783 · doc1.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,616 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 19:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,048 | $159.80 | $167,472.39 |
DisclosureSEC source: 0001567619-21-020783 · doc1.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,716 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $159.23 to $160.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 19:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,052 | $158.79 | $484,623.42 |
DisclosureSEC source: 0001567619-21-020783 · doc1.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,764 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $158.19 to $159.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 19:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $157.55 | $126,038.48 |
DisclosureSEC source: 0001567619-21-020783 · doc1.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,816 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $157.02 to $157.845. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 19:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $164.58 | $49,374.00 |
DisclosureSEC source: 0001567619-21-019298 · doc1.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,616 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $164.55 to $164.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 19:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,906 | $163.89 | $476,264.05 |
DisclosureSEC source: 0001567619-21-019298 · doc1.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,916 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $163.50 to $164.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 19:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,494 | $163.10 | $243,669.16 |
DisclosureSEC source: 0001567619-21-019298 · doc1.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,822 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $162.50 to $163.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 19:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $161.52 | $16,152.00 |
DisclosureSEC source: 0001567619-21-019298 · doc1.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,316 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 19:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $160.75 | $16,075.00 |
DisclosureSEC source: 0001567619-21-019298 · doc1.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,416 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 19:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $160.33 | $16,033.00 |
DisclosureSEC source: 0001567619-21-019298 · doc1.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,516 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 17:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $152.20 | $45,659.04 |
DisclosureSEC source: 0001567619-21-018503 · doc1.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,616 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $151.79 to $152.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 17:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $151.41 | $45,423.99 |
DisclosureSEC source: 0001567619-21-018503 · doc1.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,916 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $151.03 to $151.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 17:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,400 | $150.51 | $662,259.84 |
DisclosureSEC source: 0001567619-21-018503 · doc1.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,216 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $150.00 to $150.96. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 16:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,000 | $150.18 | $750,899.00 |
DisclosureSEC source: 0001567619-21-018209 · doc1.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,616 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $150.00 to $150.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 19:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,169 | $157.75 | $184,404.49 |
DisclosureSEC source: 0001209191-21-056956 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,616 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $157.26 to $158.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 19:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,631 | $156.72 | $255,613.09 |
DisclosureSEC source: 0001209191-21-056956 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,785 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $156.25 to $157.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 19:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,500 | $155.69 | $233,533.50 |
DisclosureSEC source: 0001209191-21-056956 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,416 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $155.19 to $156.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 19:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $154.45 | $108,117.03 |
DisclosureSEC source: 0001209191-21-056956 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,916 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $154.085 to $154.97. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 19:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 296 | $179.15 | $53,029.52 |
DisclosureSEC source: 0001209191-21-054901 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,616 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $179.12 to $179.19. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 19:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,104 | $178.34 | $196,883.83 |
DisclosureSEC source: 0001209191-21-054901 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,912 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $178.06 to $178.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 19:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,300 | $177.62 | $408,534.51 |
DisclosureSEC source: 0001209191-21-054901 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,016 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $177.06 to $178.035. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 19:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,000 | $176.36 | $176,356.00 |
DisclosureSEC source: 0001209191-21-054901 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,316 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $175.93 to $176.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 19:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $175.36 | $52,607.49 |
DisclosureSEC source: 0001209191-21-054901 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,316 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $174.87 to $175.615. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 18:56 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $160.56 | $96,337.98 |
DisclosureSEC source: 0001209191-21-052383 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,616 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $160.45 to $161.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 18:56 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,790 | $159.93 | $446,216.14 |
DisclosureSEC source: 0001209191-21-052383 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,216 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $159.40 to $160.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 18:56 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,310 | $158.84 | $208,076.34 |
DisclosureSEC source: 0001209191-21-052383 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,006 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $158.395 to $159.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 18:56 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $157.31 | $47,193.99 |
DisclosureSEC source: 0001209191-21-052383 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,313 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $156.83 to $157.72. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 16:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $184.99 | $18,499.00 |
DisclosureSEC source: 0001209191-21-049653 · doc4.xml · nonDerivative · entry 7 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,616 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 16:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $183.90 | $36,780.00 |
DisclosureSEC source: 0001209191-21-049653 · doc4.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,716 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $183.62 to $184.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 16:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $182.74 | $73,096.00 |
DisclosureSEC source: 0001209191-21-049653 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,916 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $182.35 to $183.13. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.